Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 5

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 2
Chunk 5
---
 non-GAAP measure of change in net revenues at constant currency rates, when used in conjunction with the GAAP measure of change in net revenues at actual currency rates, may provide a more complete understanding of the company’s operations and can facilitate analysis of the company’s results of operations, particularly in evaluating performance from one period to another.

Three months endedJune 30,Percent changeSix months endedJune 30,Percent changeAt actual currency ratesAt constant currency ratesAt actual currency ratesAt constant currency rates(dollars in millions)2025202420252024United States$11,762 $11,106 5.9 %5.9 %$21,741 $20,147 7.9 %7.9 %International3,661 3,356 9.1 %8.4 %7,025 6,625 6.0 %8.3 %Net revenues$15,423 $14,462 6.6 %6.5 %$28,766 $26,772 7.4 %8.0 %

2025 Form 10-Q | 30

The following table details AbbVie’s worldwide net revenues: Three months endedJune 30,Percent changeSix months endedJune 30,Percent changeAt actual currency ratesAt constant currency ratesAt actual currency ratesAt constant currency rates(dollars in millions)2025202420252024ImmunologySkyriziUnited States$3,843 $2,340 64.3 %64.3 %$6,762 $3,996 69.2 %69.2 %International580 387 49.7 %47.2 %1,086 739 46.9 %49.6 %Total$4,423 $2,727 62.2 %61.8 %$7,848 $4,735 65.8 %66.2 %RinvoqUnited States$1,452 $1,017 42.7 %42.7 %$2,672 $1,742 53.3 %53.3 %International576 413 39.6 %37.5 %1,074 781 37.6 %40